Exploring per-base quality scores as a surrogate marker of cell-free DNA fragmentome
preprint
OA: closed
Abstract
Per-base quality scores are widely treated as technical metadata in next-generation sequencing. Here, we show that in rigorously controlled whole-genome sequencing of cell-free DNA, quality profiles may encode fragmentomic signals that enable classification of cancer samples against matched controls. Analyzing four independent batches (23 cancer samples: pancreatic and breast; 22 matched controls) sequenced in a within-lane regime and further normalized per flow-cell tile to reduce technical confounders, we demonstrate through unsupervised analysis that boundary-enriched dynamics captured in these quality scores consistently separate cancer from control samples. A leave-one-batch-out classifier trained on quality-derived scores achieved a pooled area under the curve of 0.81. Furthermore, we show that the quality-derived metric correlates with short-fragment enrichment and tumor-associated 5’-end motifs, performing comparably to established, motif-based orthogonal methods. These results provide initial evidence that quality scores could serve as a low-cost, alignment-free biomarker for cfDNA-based cancer detection. Key Points PBQS in rigorously controlled cfDNA whole-genome sequencing contain biologically informative fragmentomic signal rather than only technical noise Boundary-enriched quality dynamics distinguish cancer samples from matched controls across independent sequencing batches A leave-one-batch-out classifier based on PBQS-derived features achieved a pooled AUC of 0.81 across 23 cancer and 22 control samples The PBQS-derived score correlates with short-fragment enrichment and tumor-associated 5′ end motifs, supporting its value as a lightweight orthogonal biomarker for cfDNA cancer. Biographical Note Prof. Noam Shomron heads the Functional Genomics Laboratory at Tel Aviv University’s Medical School, where his group studies genomics and bioinformatics with a focus on sequencing technologies and translational medicine.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00